Eight Trade Ideas and A Recap of our Latest
Most Popular - Vascepa’s commercial prospects are one of the hottest topics of debate in biotechnology, and this week PropThink outlined why you can trade Amarin (AMRN) in … Continue Reading
Read NowRecap
The Wrap-Up: PropThink’s Top Picks this Week
Long Ideas - ResMed (RMD) is suing a new and low-cost competitor in the Continues Positive Airway Pressure market. The target, 3B Medical, isn’t taking the litigation lying … Continue Reading
Read NowPropThink’s Week in Healthcare Equities
Long Ideas - Mr. Deryugin had an inkling that Immunomedics would get some attention this year for its ADC program, and the stock has climbed 25% since PropThink’s … Continue Reading
Read NowTrading Biotech: A Taste of PropThink this Past Week
Long Ideas - Sunshine Heart has rallied 20% since dropping to $5.00 in mid-May following an equity financing. PropThink’s subscribers knew to buy the dip, and on Monday, … Continue Reading
Read NowPropThink’s Weekly Biotech Round-Up
Long Ideas - Cell therapy developers Athersys and Cytomedix target the immense stroke treatment market. Mr. Napodano laid out the theses for these two stem cell developers, although … Continue Reading
Read NowWeekly Recap: A Few of Our Latest Trades in Healthcare
Long Ideas - For those that missed it last week, Dr. Chaudhry offered an educational, retrospective look at both AVEO and DCTH’s advisory panel votes. In addition, we … Continue Reading
Read NowPropThink’s Biotech Longs and Shorts this Week
Long Ideas - This week was dominated by a number of binary events (which we outlined on Monday), two of which played out against us; Dr. Chaudhry expected that … Continue Reading
Read Now